iHuman Inc.
iHuman Inc. is a biopharmaceutical company focused on the discovery and development of novel drug candidates, primarily in the field of oncology and autoimmune diseases.
Business. iHuman Inc. is a biopharmaceutical company focused on the discovery and development of novel drug candidates, primarily in the field of oncology and autoimmune diseases.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ2 2026 earnings (expected)2026-07-28 · estimated
- Macro
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-07-08 · AU
- Rate decisionBank of Canada rate decision (press conf.)2026-07-15 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-07-16 · EU
- Rate decisionBank of Japan rate decision (press conf.)2026-07-16 · JP
- Rate decisionFederal Reserve rate decision (press conf.)2026-07-29 · US
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
iHuman Inc. is a biopharmaceutical company focused on the discovery and development of novel drug candidates, primarily in the field of oncology and autoimmune diseases.
iHuman Inc. operates with a market price of $1.67 per share, but no liquidity metrics or valuation snapshots are available to assess its capital structure or financial health. The absence of a financial snapshot and source documents limits the ability to evaluate its debt-to-equity ratio, cash reserves, or working capital position.
Profitability and return metrics cannot be assessed due to the lack of financial data. Industry_config preferred metrics such as EBITDA margins, ROIC, or net profit margins are not available for comparison with cohort medians. This absence of data prevents a meaningful evaluation of the company's operational efficiency or return on invested capital.
Segment and geographic exposure data are not available in the current dataset. Without revenue breakdowns by business line or region, it is not possible to determine whether the company is concentrated in a single therapeutic area or geographic market.
Growth trajectory is also indeterminate. No revenue history or outlook data is available to assess the company's performance over time or its projected growth in the current or next fiscal year. The lack of numerical deltas or directional indicators prevents a clear assessment of its growth potential.
Risk factors remain unquantified. The risk assessment is marked as unknown for liquidity and dilution, with no source documents or observations available to support a more detailed analysis. The absence of financial data and filings limits the ability to evaluate dilution potential or the impact of recent capital-raising activities.
Recent events are limited to sparse text observations from public filings. No specific financial disclosures, earnings transcripts, or material events are available to inform the company's strategic direction or operational performance.
- iHuman Inc. is a biopharmaceutical company with a focus on oncology and autoimmune disease drug discovery.
- The company is currently unclassified across all dimensions, with low confidence in its classification.
- No financial data is available to assess liquidity, profitability, or capital structure.
- Growth trajectory and risk factors cannot be evaluated due to the lack of numerical data and source documents.
- Recent public filings contain only sparse text observations, limiting insight into the company's strategic or financial developments.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Regulatory filings
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- iHuman Inc. company facts · 2026-05-28
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Insider activity
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Net income (YoY) (2025-12-31 vs 2024-12-31): 1.0%Derived (calculated)
- Gross profit (YoY) (2025-12-31 vs 2024-12-31): -10.7%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 7.0%Derived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.37xDerived (calculated)
- Current ratio (FY 2025-12-31): 3.57xDerived (calculated)
- Return on assets (FY 2025-12-31): 7.0%Derived (calculated)
- Return on equity (FY 2025-12-31): 9.6%Derived (calculated)
- Gross margin (FY 2025-12-31): 67.9%Derived (calculated)
- Net margin (FY 2025-12-31): 11.8%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 0.0%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 0.0%Derived (calculated)
- Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): -4.0%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -15.1%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 0.6%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 8.1%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): -8.7%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): -12.2%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -3.1%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -8.5%Derived (calculated)
- Cash & equivalents (annual): USD 164.61MSEC XBRL filing
- Current assets (annual): USD 185.66MSEC XBRL filing
- Shareholders' equity (annual): USD 142.31MSEC XBRL filing
- Cost of revenue (annual): USD 37.09MSEC XBRL filing
- Total assets (annual): USD 195.67MSEC XBRL filing